Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536281 | 0.81 | KDM4E (0.31) | — | |
| SCHEMBL19924618 | 0.74 | ALDH1A1 (0.43) | ALDH1A1TSHR | |
| SCHEMBL22341278 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL967292 | 0.72 | PGR (0.31) | ALDH1A1TSHR | |
| SCHEMBL8059768 | 0.71 | CA12 (0.32) | ALDH1A1TSHR | |
| SCHEMBL8059662 | 0.70 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL4531420 | 0.69 | CASP1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL8041734 | 0.68 | — | — | |
| SCHEMBL7111335 | 0.67 | — | — | |
| SCHEMBL10978747 | 0.67 | ALDH1A1 (0.45) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200268762-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | HOFFMANN-LA ROCHE INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-10752630-B2 | 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection | HOFMANN LA-ROCHE INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190256515-A1 | NOVEL SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752630-B2 | 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection | FURIN, UGT1A7, SARS1 | ALDH1A1 229/4885TSHR 4339/4885 |
| US-20190256515-A1 | NOVEL SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, SULT1A1 | ALDH1A1 252/4885TSHR 4350/4885 |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | FURIN, UGT1A7, SARS1 | ALDH1A1 229/4885TSHR 4339/4885 |
| US-20200268762-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | SULT1E1, SULT1A1, UGT2B7 | ALDH1A1 40/4885TSHR 4071/4885 |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, UGT1A7 | ALDH1A1 235/4885TSHR 4523/4885 |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | TPMT, UGT1A7, UGT2B7 | ALDH1A1 132/4885TSHR 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.